FMP
Infinity Pharmaceuticals, Inc.
INFI
NASDAQ
Inactive Equity
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
0.008 USD
-0.0088 (-110%)
2023 Q2
2023 Q1
2022 Q4
2022 Q3
583k
731k
543k
712k
352k
441k
327k
429k
231k
290k
216k
283k
10.35M
11.8M
9.75M
11.16M
6.6M
5.85M
6.96M
7.66M
3.75M
5.94M
2.79M
3.5M
0
0
0
0
3.75M
5.94M
2.79M
3.5M
352k
441k
1.56M
429k
-10.12M
-11.51M
-9.54M
-10.88M
164k
462k
308k
164k
-9.96M
-11.04M
-9.23M
-10.72M
45k
-417k
-459k
-164k
-9.96M
-10.63M
-8.77M
-10.55M
-0.11
-0.12
-0.1
-0.12
-0.11
-0.12
-0.1
-0.12
89.89M
89.41M
89.25M
89.39M
89.89M
89.41M
89.25M
89.39M
-10.01M
-11.4M
-9.54M
-10.77M
2023 Q2
2023 Q1
2022 Q4
2022 Q3
-867M
-855.95M
-846.72M
-836M
-9.96M
-10.63M
-8.77M
-10.55M
0
0
0
0
0
0
0
0
-876.95M
-867M
-855.95M
-846.72M
-9.96M
-11.04M
-9.23M
-10.72M
2023 Q2
2023 Q1
2022 Q4
2022 Q3
1.08M
1.29M
800k
1.7M
106k
105k
106k
111k
0
0
17k
0
976k
1.19M
677k
1.59M
2023 Q2
2023 Q1
2022 Q4
2022 Q3
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.